VANCOUVER, BRITISH COLUMBIA -- (Marketwired) -- 02/26/14 -- Verisante Technology, Inc. (TSX VENTURE: VRS)(OTCQX: VRSEF) (the "Company" or "Verisante"), a leader in cancer detection technology, announced today that the Company has hired Jason Mangler as Director of Sales to guide the Company's world-wide sales and marketing strategy. Verisante has also hired Kim Ellis, as the Company's Sales Representative for Western Canada.
"I'm excited to be part of the Verisante organization and am looking forward to playing a leadership role in Sales and Marketing for the Company," says Jason Mangler. "I am committed to bringing innovative solutions to the market that I have spent the past decade serving."
Jason joins Verisante after more than 15 years of sales and sales management experience, ten of those in progressive roles with General Electric. As Director of Sales, Jason will be responsible for developing and executing Verisante's market development and sales plans. He will supervise the Company's sales and marketing team to identify market opportunities and fulfill market needs, ensure delivery of quality solutions, and meet both short and long term business goals.
Joining Jason on the Sales team is Kim Ellis, who has extensive experience with technical sales and training, and who, as a melanoma survivor, also has a depth of knowledge of skin cancer.
"I'm passionate about this technology because I know it works. After all else was said and done, it was an Aurascan that helped identify one of my skin lesions as cancerous," said Kim Ellis. "I'm excited to help bring this technology to medical professionals across Canada."
"Verisante is proud to welcome Jason and Kim to the Company as we prepare our full market release of Aura and continue our sales efforts to the research community," said Thomas Braun, President and CEO.
Following an extensive limited market release and testing year in 2013, Verisante is focused on developing and materializing commercial revenue generating opportunities for the Company. Verisante is gearing up for a full product launch for Aura in Canada and Europe while concurrently pursuing FDA approval for the product in the United States. The Company is also continuing the completion of a Verisante Core device for the detection of lung cancer to be submitted for regulatory approvals. The Core, which utilizes the same proprietary cancer detection platform as Aura, has the potential to be used for the detection of other internal cancers including colorectal and cervical.
About Verisante Technology, Inc.
Verisante is a medical device company committed to commercializing innovative systems for the early detection of cancer. The Verisante Aura for skin cancer detection and the Verisante Core series for lung, colon and cervical cancer detection utilize a proprietary cancer detection platform, while the operating software and probe technology are unique to each device. The cancer detection platform was developed by the BC Cancer Agency and tested and refined at the Skin Care Centre at Vancouver General Hospital. This exclusive platform technology allows Verisante to develop and offer a range of compact, non-invasive cancer detection devices that offer physicians immediate results for many of the most common cancers. Aura has been approved for sale in Canada, Europe and Australia. Core has not yet been approved for sale.
Verisante Aura was awarded Popular Science Magazine's "Best of What's New Award" for 2011, was awarded a 2013 Prism Award for Innovation in Photonics, as well as an Edison Award for Excellence in Innovation in 2013. Verisante Core was named one of the top 10 cancer breakthroughs of 2011 by the Canadian Cancer Society.
The TSX Venture Exchange has neither approved nor disapproved of the contents of this press release. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.
This release contains forward-looking statements, including, but not limited to, statements regarding the future commercialization of medical devices, the market demand for these products and the proprietary protections the Company will obtain with regard to the technology, all of which statements are subject to market risks, and the possibility that the Company will not be able to obtain patent protection or obtain sufficient customer demand. These statements are made based upon current expectations and actual results may differ from those projected due to a number of risks and uncertainties.